DURATION OF DIABETES AND CARDIORENAL EFFICACY OF LIRAGLUTIDE AND SEMAGLUTIDE: A POST HOC ANALYSIS OF THE LEADER AND SUSTAIN-6 CLINICAL TRIALS

被引：0
|
作者：
Verma, Subodh [1 ]
Bain, Stephen C. [1 ]
Honore, Julie Broe [1 ]
Fries, Tea Monk [1 ]
Nauck, Michael A. [1 ]
Pratley, Richard E. [1 ]
Rasmussen, Soren [1 ]
Zinman, Bernard [1 ]
Buse, John [1 ]
机构：
[1] Novo Nordisk AS, Soborg, Denmark
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2019年 / 73卷 / 09期
关键词：
D O I：
10.1016/S0735-1097(19)32310-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1024-05
引用
收藏
页码：1704 / 1704
页数：1
相关论文
共 50 条
  • [21] SUSTAIN 6: a post-hoc analysis of the effect of semaglutide on cardiovascular outcomes over time in subjects with type 2 diabetes
    Jodar, E.
    Seufert, J.
    Damgaard, L. H.
    Holst, A. G.
    Leiter, L. A.
    [J]. EUROPEAN HEART JOURNAL, 2017, 38 : 819 - 819
  • [22] Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: Post-hoc analysis
    Araki, Eiichi
    Harashima, Shinichi
    Nishida, Tomoyuki
    Nakamura, Jiro
    [J]. JOURNAL OF DIABETES INVESTIGATION, 2022, : 1971 - 1980
  • [23] EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES - A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS
    Perkovic, Vlado
    Bain, Stephen
    Bakris, George
    Buse, John
    Idorn, Thomas
    Mahaffey, Kenneth
    Marso, Steven
    Nauck, Michael
    Pratley, Richard
    Rasmussen, Soren
    Rossing, Peter
    Tornoe, Karen
    Zinman, Bernard
    Mann, Johannes
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 : 338 - 338
  • [24] REDUCTION IN THE RATE OF EGFR DECLINE WITH SEMAGLUTIDE VS PLACEBO: A POST HOC POOLED ANALYSIS OF SUSTAIN 6 AND PIONEER 6
    Tuttle, Katherine
    Cherney, David
    Hadjadj, Samy
    Idorn, Thomas
    Mosenzon, Ofri
    Perkovic, Vlado
    Rasmussen, Soren
    Wolthers, Benjamin
    Bain, Stephen C.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 183 - 183
  • [25] Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6
    Husain, Mansoor
    Consoli, Agostino
    De Remigis, Alessandra
    Meyer, Anna Sina Pettersson
    Rasmussen, Soren
    Bain, Stephen
    [J]. CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [26] Efficacy of Semaglutide by Background Sodium-Glucose Cotransporter 2 Inhibitor: A Post Hoc Analysis of SUSTAIN 9
    Zinman, Bernard
    Bhosekar, Vaishali
    Busch, Robert S.
    Holst, Ingrid
    Ludvik, Bernhard
    Thrasher, James
    Woo, Vincent C.
    Philis-Tsimikas, Athena
    [J]. DIABETES, 2019, 68
  • [27] Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6
    Mansoor Husain
    Agostino Consoli
    Alessandra De Remigis
    Anna Sina Pettersson Meyer
    Søren Rasmussen
    Stephen Bain
    [J]. Cardiovascular Diabetology, 21
  • [28] CHANGE IN KDIGO KIDNEY RISK CATEGORY WITH SEMAGLUTIDE TREATMENT-A POST HOC ANALYSIS OF THE SUSTAIN 6 TRIAL
    Tuttle, Katherine
    Bain, Stephen C.
    Cherney, David
    Lawson, Jack
    Rasmussen, Soren
    Vrhnjak, Blaz
    Khunti, Kamlesh
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I331 - I331
  • [29] The effect of semaglutide once weekly on MACE and blood pressure by race and ethnicity: SUSTAIN 6 post hoc analysis
    Desouza, C.
    Bain, S. C.
    Gondolf, T.
    Hansen, T.
    Holst, I.
    Rea, R. R.
    Seufert, J.
    [J]. EUROPEAN HEART JOURNAL, 2019, 40 : 3876 - 3876
  • [30] Impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide among participants with type 2 diabetes: A post hoc analysis of SUSTAIN China
    Ji, Linong
    Lu, Yibing
    Shen, Zewei
    Hu, Ping
    Liu, Wenyan
    Zhang, Qiu
    Shi, Bimin
    [J]. DIABETES OBESITY & METABOLISM, 2024,
12345